The Uprising Role of Histone Deacetylase Inhibitors in Cancer Therapy
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 20 August 2024 | Viewed by 1176
Special Issue Editors
Interests: surgery; transplantation; surgical oncology; oncology; experimental surgery
Special Issues, Collections and Topics in MDPI journals
Interests: surgery; hepatocellular carcinoma; targeted therapies
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Histone modification, which occurs through the process of acetylation, plays a key role in the epigenetic regulation of gene expression. The balance between histone deacetylases (HDAC) and histone acetyltransferases (HAT) controls this process. HDAC inhibitors (HDACI) can induce cancer cell cycle arrest, differentiation, and cell death, reduce angiogenesis, and modulate immune response. Therefore, HDACI represent a group of enzymes that can be used for the development of pharmaceutical agents against a variety of malignant neoplastic diseases. Mechanisms of HDACI anticancer effect depends on many factors. HDACIs vorinostat, romidepsin, and belinostat have been approved for some T-cell lymphoma and panobinostat for multiple myeloma. Other HDACI are in clinical trials for the treatment of hematological and solid malignancies. The results of such studies are promising, but further larger studies are needed.
Dr. Christos Damaskos
Dr. Nikolaos Garmpis
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- histone
- acetylation
- deacetylation
- inhibitor
- cancer
- targeted
- therapy
- epigenetics
